ERBB2 and breast cancer: 177Lu-labeled trastuzumab administered to patients with HER2-positive BC localized in primary and metastatic tumors and these were detected by single photon emission computed tomography/computed tomography (SPECT/CT) illustrating its potential for imaging and RIT of HER2-positive BC (Bhusari et al. 2017).